

## Package leaflet: information for the user

### Paclitaxel 6 mg/ml concentrate for solution for infusion

#### Paclitaxel

The name of your medicine is 'Paclitaxel 6 mg/ml concentrate for solution for infusion' but in the rest of the leaflet it will be called "Paclitaxel".

**Read all of this leaflet carefully before you start using this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### What is in this leaflet:

1. What Paclitaxel is and what it is used for
2. What you need to know before you use Paclitaxel
3. How to use Paclitaxel
4. Possible side effects
5. How to store Paclitaxel
6. Contents of the pack and other information

#### 1. What Paclitaxel is and what it is used for

Paclitaxel belongs to a group of anti-cancer medicines called taxanes. These agents inhibit the growth of cancer cells.

Paclitaxel is used to treat:

##### **Ovarian cancer:**

- as first-line therapy (after initial surgery in combination with the platinum-containing medicine cisplatin).
- after standard platinum-containing medicines have been tried but did not work.

##### **Breast cancer:**

- as first-line therapy for advanced disease or disease which has spread to other parts of the body (metastatic disease). Paclitaxel is either combined with an *anthracycline* (e.g. doxorubicin) or with a medicine called *trastuzumab* (for patients for whom anthracycline is not suitable and whose cancer cells have a protein on their surface called HER 2, see package leaflet of trastuzumab).
- as an additional treatment with anthracycline and cyclophosphamide (AC).
- as a second-line treatment for patients who have not responded to standard treatments using anthracyclines, or for whom such treatment should not be used.

##### **Advanced non-small-cell lung cancer:**

- in combination with cisplatin, when surgery and/or radiation therapy aren't suitable.

##### **AIDS-related Kaposi's sarcoma:**

- where another treatment (i.e. liposomal anthracyclines) has been tried but did not work.

## 2. What you need to know before you use Paclitaxel

### You should not be given Paclitaxel:

- if you are allergic to paclitaxel or any of the other ingredients of this medicine (listed in section 6), especially polyoxyethylated castor oil (macrogolglycerol ricinoleate).
- if you are breast-feeding.
- if you have too few white blood cells count (baseline neutrophil counts  $<1.5 \times 10^9/l$  or  $<1.0 \times 10^9/l$  for Kaposi's sarcoma patients - your doctor will advise you on this) in your blood. Your doctor will take blood samples to check this.
- **if you have a serious and uncontrolled infections (only in case paclitaxel is used to treat Kaposi's sarcoma).**

If any of these apply to you, talk to your doctor before starting treatment with Paclitaxel.

Paclitaxel is not recommended for use in children (under 18 years).

### Warnings and precautions

Talk to your doctor before using Paclitaxel

To minimize allergic reactions, you will be given other medicines before you receive Paclitaxel.

- if you experience allergic reactions (for example difficulty breathing, shortness of breath, chest tightness, drop in blood pressure, dizziness, light headedness, skin reactions such as rash or swelling).
- if you have fever, severe chills, sore throat or mouth ulcers (signs of bone marrow suppression).
- if you have numbness, tingling, pricking sensations, sensitivity to touch, or weakness of the arms and legs (signs of peripheral neuropathy); a dose reduction of Paclitaxel may be necessary.
- if you have severe liver problems; in that case the use of Paclitaxel is not recommended.
- if you have heart conduction problems.
- if you develop severe or persistent diarrhoea, with fever and stomach pain, during or shortly after the treatment with Paclitaxel. Your colon could be inflamed (pseudomembranous colitis).
- if you had previous radiation to your chest (because it may increase the risk of lung inflammation).
- if you have a sore or red mouth (signs of mucositis) and are treated for Kaposi's Sarcoma. You may need a lower dose.

Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.

### Tell your doctor immediately if any of these apply to you.

Paclitaxel should always be administered into veins. Administration of Paclitaxel in the arteries can cause inflammation of the arteries, and you can suffer from pain, swelling, redness and heat.

### Other medicines and Paclitaxel

Speak to your doctor when taking paclitaxel at the same time as any of the following:

- medicines for treating infections (i.e. antibiotics such erythromycin, rifampicin, etc.; ask your doctor, nurse or pharmacist if you are unsure whether the medicine you are taking is an antibiotic), and including medicines for treating fungal infections (e.g. ketoconazole)
- medicines used to help you stabilize your mood also sometimes referred to as anti-depressants (e.g. fluoxetine)
- medicines used to treat seizures (epilepsy) (e.g. carbamazepine, phenytoin)
- medicines used to help you lower blood lipid levels (e.g. gemfibrozil)
- medicine used for heartburn or stomach ulcers (e.g. cimetidine)
- medicines used to treat HIV and AIDS (e.g. ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, nevirapine)
- a medicine called clopidogrel used to prevent blood clots.

The amount of alcohol in this medicine may alter the effects of other medicines. Talk to your doctor or pharmacist if you are taking other medicines.

### **Pregnancy, breast-feeding and fertility**

**Tell your doctor if you are pregnant** or think you may be pregnant before receiving treatment with Paclitaxel. If there is a chance that you could become pregnant, **use an effective and safe method of contraception during treatment**. Paclitaxel should not be used during pregnancy unless clearly necessary.

Female and male patients of fertile age, and/or their partners should use contraception for at least 6 months after treatment with paclitaxel. Male patients should seek advice regarding cryoconservation of sperm prior to treatment with paclitaxel because of the possibility of irreversible infertility.

**If you are breast-feeding, tell your doctor.** It is not known if paclitaxel passes into breast milk. Because of the possibility of harm to the infant stop breast-feeding if you are taking Paclitaxel. Do not restart breast-feeding unless your doctor has allowed you to.

### **Driving and using machines**

There is no reason why you cannot continue driving between courses of Paclitaxel but you should remember that this medicine contains some alcohol and it may be unwise to drive or use machines immediately after a course of treatment due to possible effects on your central nervous system. As in all cases, you should not drive or use machines if you feel dizzy or light-headed.

The amount of alcohol in this medicine can affect your ability to drive or use machines. This is because it may affect your judgement and how fast you react.

### **Paclitaxel contains castor oil (macroglycerol ricinolate) and alcohol**

Paclitaxel contains castor oil that may cause severe allergic reactions. If you are allergic to castor oil, talk to your doctor before you receive Paclitaxel.

This medicine contains 393 mg of alcohol (ethanol) in 1 ml which is equivalent to 39.3 % w/v. The amount in 52.5 ml of this medicine is equivalent to 515.8 ml of beer or 206.3 ml of wine.

If you have epilepsy or liver problems, talk to your doctor or pharmacist before taking this medicine.

If you are addicted to alcohol, talk to your doctor or pharmacist before taking this medicine.

## **3. How to use Paclitaxel**

- To minimise allergic reactions, you will be given other medicines before starting Paclitaxel. These medicines can be given as either tablets or infusion into a vein or both.
- You will receive paclitaxel as a drip into one of your veins (by intravenous infusion), through an in-line filter. Paclitaxel will be administered to you by a healthcare professional. He or she will prepare the solution for infusion before it is given to you. The dose you receive will also depend on results of your blood tests. Depending on the type and severity of the cancer you will receive Paclitaxel either alone or in combination with another anticancer agent.
- Paclitaxel should always be administered into one of your veins over a period of 3 or 24 hours. It is usually given every 2 or 3 weeks, unless your doctor decides otherwise. Your doctor will inform you about the number of courses of Paclitaxel you need to receive.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

## **4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Tell your doctor immediately if you notice any signs of allergic reactions.** These may include one or more of the following:

- flushing,
- skin reactions,
- itching,
- chest tightness,
- shortness or difficulty in breathing,
- swelling.

These can all be signs of serious side effects.

**Tell your doctor immediately if you experience:**

- **fever, severe chills, sore throat or mouth ulcers** (signs of bone marrow suppression).
- **numbness or weakness of the arms and legs** (signs of peripheral neuropathy).
- severe or persistent diarrhoea, with fever and stomach pain.

**Very common: may affect more than 1 in 10 people**

- Minor allergic reactions such as flushing, rash, itching
- Infections: mainly upper respiratory infection, urinary tract infection
- Sore throat or mouth ulcers, sore and red mouth, diarrhoea, feeling or being sick (nausea, vomiting)
- Hair loss (the majority of cases of hair loss happened less than one month after starting paclitaxel. When it happens, hair loss is pronounced (over 50%) in the majority of patients).
- Pain in the muscles, cramps, pain in the joints
- Numbness, tingling or weakness in arms and legs (all symptoms of peripheral neuropathy)\*  
\*Can persist beyond 6 months of paclitaxel discontinuation
- Tests may show: reduction of blood platelet count which can lead to bleeding and bruising more easily than normal, white or red blood cells count, low blood pressure

**Common side: may affect up to 1 in 10 people**

- Temporary mild nail change and skin changes, reactions at injection sites (localised swelling, pain, and redness of the skin)
- Tests may show: slower heart rate, severe elevation in liver enzymes (alkaline phosphatase and AST - SGOT)

**Uncommon: may affect up to 1 in 100 people**

- Shock due to infections (known as 'septic shock')
- Palpitations, cardiac dysfunction (AV block, cardiomyopathy), rapid beating of the heart, heart attack, respiratory distress
- Fatigue, sweating, fainting (syncope), significant allergic reactions, phlebitis (inflammation of a vein), swelling of the face, lips, mouth, tongue or throat
- Back pain, chest pain, pain around hands and feet, chills, abdominal (tummy) pain
- Tests may show: severe elevation of bilirubin (jaundice), high blood pressure, and blood clot.

**Rare: may affect up to 1 in 1,000 people**

- Shortage of white blood cells with fever and increased risk of infection (febrile neutropenia)
- Affection of nerves with feeling of weakness in muscles of arms and legs (motor neuropathy)
- Heart failure (Cardiac failure)
- Shortness of breath, pulmonary embolism, lung fibrosis, interstitial pneumonia, dyspnoea, pleural effusion
- Bowel obstruction, bowel perforation, inflammation of colon (ischaemic colitis), inflammation of the pancreas (pancreatitis)
- Pruritus, rash, skin redness (erythema)
- Blood poisoning (sepsis), peritonitis, pneumonia
- Pyrexia, dehydration, asthenia, oedema, malaise
- Serious and potentially fatal hypersensitivity reactions (anaphylactic reactions)
- Tests may show: increase in blood creatinine indicating renal function impairment

**Very rare: may affect up to 1 in 10,000 people**

- Irregular rapid heart rhythm (atrial fibrillation, supraventricular tachycardia)
- Sudden disorder in blood forming cells (acute myeloid leukaemia, myelodysplastic syndrome)
- Optic nerve and/or visual disturbances (scintillating scotomata)
- Hearing loss or reduction (ototoxicity), ringing in the ears (tinnitus), vertigo
- Cough
- Blood clot in a blood vessel of abdomen and bowel (mesenteric thrombosis), inflammation of colon sometimes with persistent severe diarrhoea (pseudomembranous colitis, neutropenic colitis), dropsy (ascites), oesophagitis, constipation.
- Serious hypersensitivity reactions including fever, skin redness, pain in joints and/or inflammation of the eye (Stevens-Johnson syndrome), local peeling of the skin (epidermal necrolysis), redness with irregular red (exudative) spots (erythema multiforme), inflammation of the skin with blisters and peeling (exfoliative dermatitis), urticaria, loose nails (patients on therapy should wear sun protection on hands and feet).
- Loss of appetite (anorexia).
- Serious and potentially fatal hypersensitivity reactions with shock (anaphylactic shock).
- Disturbed liver function (hepatic necrosis, hepatic encephalopathy (both with reported cases of fatal outcome))
- Confusional state.
- Grand mal seizures, brain nerve disorder (autonomic neuropathy; affection of the involuntary body functions, this can result in ileus and low blood pressure), convulsions, brain disease (encephalopathy), dizziness, headache, problems with coordination (ataxia)

**Not known: frequency cannot be estimated from the available data**

- Rapid destruction of tumors (tumor lysis syndrome)
- Fluid collection in the macula of the eye (Macular edema), presence of perceived flashes of light in the eye (photopsia), deposits within the eye's vitreous humour (vitreous floaters)
- Inflammation of the veins (Phlebitis)
- Thickening and hardening of the skin as well as the blood vessels and the internal organs (Scleroderma)
- "Butterfly rash" (Systemic lupus erythematosus)
- Coagulation disorders (Disseminated intravascular coagulation, or "DIC," has been reported. This concerns a serious condition that makes people bleed too easily, get blood clots too easily, or both).
- Redness and swelling of the palms of your hands or soles of your feet which may cause your skin to peel

**Reporting of side effects**

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:

For UK - Yellow Card Scheme

Website: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

For IE – HPRa Pharmacovigilance

Website: [www.hpra.ie](http://www.hpra.ie)

By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Paclitaxel**

Keep this medicine out of the sight and reach of children.

Do not store above 25°C.

Keep the vial in the outer carton in order to protect from light.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.

Do not use this medicine if you notice cloudy solution or an insoluble precipitate.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## **6. Contents of the pack and other information**

### **What Paclitaxel contains**

- The active substance is paclitaxel . Each ml of concentrate for solution for infusion contains 6 mg of paclitaxel.
  - One 5 ml vial contains 30 mg paclitaxel.
  - One 16.7 ml vial contains 100 mg paclitaxel.
  - One 25 ml vial contains 150 mg paclitaxel.
  - One 50 ml vial contains 300 mg paclitaxel.
  - One 100 ml vial contains 600 mg paclitaxel.
- The other ingredients are ethanol anhydrous, macrogolglycerol ricinoleate and citric acid anhydrous (for pH adjustment)

### **What Paclitaxel looks like and contents of the pack**

Concentrate for solution for infusion.

Paclitaxel is a clear, slightly yellowish solution.

Paclitaxel is available in glass vials. The glass vials are sealed with chlorobutyl or bromobutyl rubber stopper with aluminium seal and plastic flip-off cap.

#### Pack sizes:

Packs containing 1 or 5 glass vials.

Not all pack sizes may be marketed.

### **Marketing Authorisation Holder**

For UK:

Fresenius Kabi Limited  
Cestrian Court  
Eastgate Way, Manor Park  
Runcorn, Cheshire, WA7 1NT  
UK

For IE:

Fresenius Kabi Deutschland GmbH  
Else-Kröner-Straße 1,  
61352 Bad Homburg v.d.Höhe  
Germany

**Manufacturer:**

Fresenius Kabi Deutschland GmbH  
 Pfingstweide 53  
 61169 Friedberg  
 Germany

Corden Pharma Latina S.p.A.

Via Murillo No. 7  
 04013 Sermoneta (LT)  
 Italy

**This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:**

Austria	Paclitaxel Kabi 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Belgium	Paclitaxel Fresenius Kabi
Bulgaria	Paclitaxel Kabi 6 mg/ml Концентрат за инфузионен разтвор
Czech Republic	Paclitaxel Kabi
Denmark	Paclitaxel Fresenius Kabi 6 mg/ konzentrat til infusionsvaeske, opløsning
Estonia	Paclitaxel Kabi 6 mg/ml infusioonilahuse kontsentraat
Germany	Paclitaxel Kabi 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Finland	Paclitaxel Fresenius Kabi 6 mg/ml infuusiokonsentraatti, liuosta varten
France	Paclitaxel Kabi 6 mg/ml solution à diluer pour perfusion
Hungary	Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz
Ireland	Paclitaxel 6 mg/ml concentrate for solution for infusion
Italy	Paclitaxel Kabi 6 mg/ml concentrato per soluzione per infusione
Latvia	Paclitaxel Kabi 6 mg/ml koncentrāts infūziju šķīduma pagatavošanai
Lithuania	Paclitaxel Kabi 6 mg/ml koncentratas infuziniam tirpalui
Luxemburg	Paclitaxel Kabi 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Netherlands	Paclitaxel Fresenius Kabi
Norway	Paclitaxel Fresenius Kabi 6 mg/ml konsentrat til infusjonsvæske
Poland	Paclitaxel Kabi
Portugal	Paclitaxel Kabi 6 mg/ml concentrado para solução para perfusão
Romania	Paclitaxel Kabi 6 mg/ml concentrat pentru soluție perfuza
Slovakia	Paclitaxel Kabi 6 mg/ml
Slovenia	Paklitaxel Kabi 6 mg/ml koncentrat za raztopino za infundiranje
Spain	Paclitaxel Fresenius Kabi 6 mg/ml concentrado para solución para perfusión
Sweden	Paclitaxel Fresenius Kabi 6 mg/ml konzentrat till infusionsvätska, lösning
United Kingdom (Northern Ireland)	Paclitaxel 6 mg/ml concentrate for solution for infusion

**This leaflet was last revised in September 2022.**

---

**The following information is intended for healthcare professionals only:**

**Handling:** As with all antineoplastic agents, caution should be exercised when handling paclitaxel. Dilution should be carried out under aseptic conditions by trained personnel in a designated area. Adequate protective gloves should be worn. Precautions should be taken to avoid contact with the skin and mucous membranes. In the event of contact with the skin, the area should be washed with soap and water. Following topical exposure, tingling, burning and redness have been observed. In the event of contact with the mucous membranes, these should be flushed thoroughly with water. Upon inhalation, dyspnoea, chest pain, burning throat and nausea have been reported.

If unopened vials are refrigerated, a precipitate may form that redissolves with little or no agitation upon reaching room temperature. Product quality is not affected. If the solution remains cloudy or if an insoluble precipitate is noted, the vial should be discarded.

Following multiple needle entries and product withdrawals, the vials maintain microbial, chemical and physical stability for up to 28 days at 25°C. Other in-use storage times and conditions are the responsibility of the user.

The Chemo-Dispensing Pin device or similar devices with spikes should not be used since they can cause the vial stopper to collapse, resulting in loss of sterile integrity.

**Preparation for IV administration:**

Prior to infusion, paclitaxel must be diluted using aseptic techniques in 5% Glucose solution, 0.9% Sodium Chloride solution, 5% Glucose solution in Ringer solution, and 5% Glucose solution/0.9% Sodium Chloride solution to a final concentration of 0.3 to 1.2 mg/ml.

Chemical and physical in-use stability of the solution prepared for infusion has been demonstrated at 25°C for 24 hours when diluted in 5% Glucose solution, 0.9% Sodium Chloride solution, 5% Glucose solution in Ringer solution, and 5% Glucose solution/0.9% Sodium Chloride solution.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution / dilution has taken place in controlled and validated aseptic conditions.

After dilution the solution is for single use only.

Upon preparation, solutions may show haziness, which is attributed to the formulation vehicle, and is not removed by filtration. Paclitaxel should be administered through an in-line filter with a microporous membrane  $\leq 0.22 \mu\text{m}$ . No significant losses in potency have been noted following simulated delivery of the solution through IV tubing containing an in-line filter.

There have been rare reports of precipitation during paclitaxel infusions, usually towards the end of a 24 hour infusion period. Although the cause of this precipitation has not been elucidated, it is probably linked to the supersaturation of the diluted solution. To reduce the precipitation risk, Paclitaxel should be used as soon as possible after dilution, and excessive agitation, vibration or shaking should be avoided. The infusion sets should be flushed thoroughly before use. During infusion, the appearance of the solution should be regularly inspected and the infusion should be stopped if precipitation is present.

To minimise patient exposure to DEHP which may be leached from plasticised PVC infusion bags, sets, or other medical instruments, diluted Paclitaxel solutions should be stored in non-PVC bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through

polyethylene-lined administration sets. Use of filter devices (e.g. IVEX-2<sup>®</sup>) which incorporate short inlet and/or outlet plasticised PVC tubing has not resulted in significant leaching of DEHP.

*Protection instructions for preparation of Paclitaxel solution for infusion*

1. Protective chamber should be used and protective gloves as well as protective gown should be worn. If there is no protective chamber available mouth cover and goggles should be used.
2. Pregnant women or women who may become pregnant, should not handle this product.
3. Opened containers, like injection vials and infusion bottles and used canules, syringes, catheters, tubes, and residuals of cytostatics should be considered as hazardous waste and undergo disposal according to local guidelines for the handling of HAZARDOUS WASTE.
4. Follow the instructions below in case of spillage: - protective clothing should be worn - broken glass should be collected and placed in the container for HAZARDOUS WASTE - contaminated surfaces should be flushed properly with copious amounts of cold water - the flushed surfaces should then be wiped thoroughly and the materials used for wiping should be disposed as HAZARDOUS WASTE
5. In the event of paclitaxel contact with the skin, the area should be rinsed with plenty of running water and then washed with soap and water. In case of contact with mucous membranes, wash the contacted area thoroughly with water. If you have any discomfort, contact a doctor.
6. In case of contact of paclitaxel with eyes, wash them thoroughly with plenty of cold water. Contact an ophthalmologist immediately.

**Disposal:**

Any unused product or waste material should be disposed of in accordance with local requirements.